Established · publishing since 1993Rising activity
Prostate Cancer Treatment and ResearchCancer Genomics and DiagnosticsCancer, Hypoxia, and MetabolismGlioma Diagnosis and TreatmentProstate Cancer Diagnosis and Treatment
Publications
1,739
Citations
99,647
Est. group size
~195
Recurring co-author estimate
Active years
34
Publishing since 1993
In context
Among 4,953 established Medicine PIs within our index
Citations: 99,647p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 204.0p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~17 · 2% small-team papers (≤3 authors) · across 113 venues
Publication cadence
Publications per year over the last 10 years — averaging 204.0/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- STAG2 loss amplifies EWS-FLI1-driven microsatellite enhancer activity promoting Ewing sarcoma aggressiveness
Proceedings of the National Academy of Sciences · 2026
- Supplementary Figure S7 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Figure S4 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation
2026
- Supplementary Figure S10 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Supplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Figure S11 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation
2026
- Supplementary Table S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Figure S1 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation
2026
- Supplementary Table S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Supplementary Figure S2 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Figure S9 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation
2026
- Figure S2 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation
2026
- Supplementary Table S5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Supplementary Table S4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
- Supplementary Figure S6 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
2026
Publishes in
- Cancer Research×110
- Journal of Clinical Oncology×29
- bioRxiv (Cold Spring Harbor Laboratory)×19
- Neuro-Oncology×17
- Cell×16
Similar researchers
By research-topic overlap
- Arul Chinnaiyan
Medicine · University of Michigan
- Yilun Sun
Medicine · University of Michigan
- Udit Singhal
Medicine · University of Michigan
- Lakshmi P. Kunju
Medicine · University of Michigan
- Scott A. Tomlins
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile